Literature DB >> 20922827

Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations.

Lisa Hutchinson.   

Abstract

Entities:  

Year:  2010        PMID： 20922827     DOI： 10.1038/nrclinonc.2010.143

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

Authors:  M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan Powell; Katherine M Bell-McGuinn; Clare Scott; Jeffrey N Weitzel; Ana Oaknin; Niklas Loman; Karen Lu; Rita K Schmutzler; Ursula Matulonis; Mark Wickens; Andrew Tutt
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

2.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321
  2 in total
  13 in total

Review 1.  More forks on the road to replication stress recovery.

Authors:  Chris Allen; Amanda K Ashley; Robert Hromas; Jac A Nickoloff
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

2.  PARP-1 and PARP-2: New players in tumour development.

Authors:  José Yelamos; Jordi Farres; Laura Llacuna; Coral Ampurdanes; Juan Martin-Caballero
Journal:  Am J Cancer Res       Date:  2011-01-08       Impact factor: 6.166

3.  Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.

Authors:  Georg Feldmann; Collins Karikari; Marco dal Molin; Stephanie Duringer; Petra Volkmann; Detlef K Bartsch; Savita Bisht; Jan-Bart Koorstra; Peter Brossart; Anirban Maitra; Volker Fendrich
Journal:  Cancer Biol Ther       Date:  2011-06-01       Impact factor: 4.742

Review 4.  Harnessing synthetic lethal interactions in anticancer drug discovery.

Authors:  Denise A Chan; Amato J Giaccia
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

5.  Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks.

Authors:  Li-Jeen Mah; Christian Orlowski; Katherine Ververis; Raja S Vasireddy; Assam El-Osta; Tom C Karagiannis
Journal:  Genome Integr       Date:  2011-01-25

6.  PARP1 is required for chromosomal translocations.

Authors:  Justin Wray; Elizabeth A Williamson; Sudha B Singh; Yuehan Wu; Christopher R Cogle; David M Weinstock; Yu Zhang; Suk-Hee Lee; Daohong Zhou; Lijian Shao; Martin Hauer-Jensen; Rupak Pathak; Virginia Klimek; Jac A Nickoloff; Robert Hromas
Journal:  Blood       Date:  2013-04-08       Impact factor: 22.113

7.  Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.

Authors:  Yi-Hsin Hsu; Jun Yao; Li-Chuan Chan; Ting-Jung Wu; Jennifer L Hsu; Yueh-Fu Fang; Yongkun Wei; Yun Wu; Wen-Chien Huang; Chien-Liang Liu; Yuan-Ching Chang; Ming-Yang Wang; Chia-Wei Li; Jia Shen; Mei-Kuang Chen; Aysegul A Sahin; Anil Sood; Gordon B Mills; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2014-06-26       Impact factor: 12.701

Review 8.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Authors:  Nicholas B La Thangue; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

Review 9.  BRCA2: one small step for DNA repair, one giant protein purified.

Authors:  Ryan B Jensen
Journal:  Yale J Biol Med       Date:  2013-12-13

10.  Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.

Authors:  Xiaoxing Feng; David W Koh
Journal:  Int J Oncol       Date:  2012-12-17       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.